Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06182267 · ClinicalTrials.gov registry record · Phase 1

Maximal Use Study to Determine the Pharmacokinetics of L-arginine After Exaggerated Oral Use of COL101

A Phase 1 study, sponsored by Colgate Palmolive.

Completed
Registry status
Phase 1
Development phase
29
Enrollment target

NCT06182267: Completed Phase 1 study, sponsored by Colgate Palmolive.

NCT06182267 is a Phase 1 study that has completed, run by Colgate Palmolive. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06182267, a Phase 1 study, has completed, sponsored by Colgate Palmolive.

COMPLETED
Registry status
Phase 1
Development phase
29 participants
Enrollment target

Study Summary

Pharmacokinetic (PK) study of L-arginine after exaggerated oral use of the novel dentifrice product COL101 after repeated daily applications in healthy adult subjects.

Primary Outcome

Measurement of arginine in blood after oral brushing

Interventions

  • DRUG L Arginine
  • DRUG Sodium Fluoride

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2023-11-27
Est. Completion 2023-12-22
Phase Phase 1
Colgate Palmolive

51 total trials

What the finished NCT06182267 record still lists

NCT06182267 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).

The record links to 0 conditions, and to 2 interventions - of which L Arginine is the first listed.

NCT06182267 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06182267 about?

NCT06182267 is a clinical study titled "Maximal Use Study to Determine the Pharmacokinetics of L-arginine After Exaggerated Oral Use of COL101". Pharmacokinetic (PK) study of L-arginine after exaggerated oral use of the novel dentifrice product COL101 after repeated daily applications in healthy adult subjects.

What is the current status of trial NCT06182267?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2023-11-27. Estimated completion is 2023-12-22.

What interventions are being tested in trial NCT06182267?

The interventions under investigation include: L Arginine (DRUG), Sodium Fluoride (DRUG).

Who is sponsoring clinical trial NCT06182267?

This trial is sponsored by Colgate Palmolive, which has 51 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06182267's enrollment target sits among peer trials

29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06182267, the US trial registry maintained by the National Library of Medicine. NCT06182267 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.